Investor Center


Press Release

Printer Friendly Version  View printer-friendly version
<< Back
Bellicum to Present at Leerink Partners Inaugural Immuno-Oncology Roundtable Conference

HOUSTON--(BUSINESS WIRE)--Sep. 28, 2015-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced that Tom Farrell, President and CEO, is scheduled to present a business overview and update at the Leerink Partners Inaugural Immuno-Oncology Roundtable Conference on Thursday, October 1, 2015 at 2:45 p.m. EDT in New York.

The presentation will be webcast live and may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.

Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals
Investors:
Alan Musso, 832-384-1116
CFO
amusso@bellicum.com
or
Media:
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com